Limitations of dextromethorphan N-demethylation as a measure of CYP3A activity

Pharmacogenetics

Volumn 9, Issue 4, 1999, Pages 453-462

  Kashuba, Angela D M ^a,g   Nafziger, Anne N ^a,b   Kearns, Gregory L ^d,e,f   Leeder, J Steven ^d,e,f   Gotschall, Russell ^d   Gaedigk, Andrea ^d,e,f   Bertino Jr , Joseph S ^a,b,c  

^a Clin Pharmacology Research Centre   (United States)

^b Department of Medicine ^*  (United States)

^c BASSETT HEALTHCARE   (United States)

^d CHILDREN S MERCY HOSPITAL   (United States)

^e UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^g UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

CYP3A; Dextromethorphan; Midazolam; Phenotype

Indexed keywords

CYTOCHROME P450; DEXTROMETHORPHAN; FLUVOXAMINE; FLUVOXAMINE MALEATE; MIDAZOLAM;

ACCURACY; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; FOLLICULAR PHASE; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; LUTEAL PHASE; MALE; METHYLATION; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHENOTYPE; PLASMA CLEARANCE; PRIORITY JOURNAL;

EID: 0032825893     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Brosen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 1993; 45:1211-1214.
2. Carrillo JA, Dahl ML, Svensson JO, Alm C, Rodriguez I, Bertilsson L. Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity. Clin Pharmacol Ther 1996; 60:183-190.
3. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16:31-41.
4. Devine BJ. Gentamicin pharmacokinetics. Drug Intell Clin Pharm 1974; 8:650-655.
5. Ducharme J, Abdullah S, Wainer IW. Dextromethorphan as an in vivo probe for the simultaneous determination of CYP2D6 and CYP3A activity. J Chrom 1996; 678:113-128.
6. Fleishaker JC, Hulst LK. A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine. Eur J Clin Pharmacol 1994; 46:35-39.
7. Gaedigk A, Gotschall RR, Forbes NS, Simon SD, Kearns GL, Leeder JS, Misclassification analysis using an algorithm for cytochrome P4502D6 (CYP2D6) phenotype assignment from genotype data. Pharmacogenetics 1999; submitted.
8. Gonzalez FJ. Cytochrome P450 in humans. In: Schenkman JB, Greim H, eds. Cytochrome P450. Berlin: Springer-Verlag; 1993. pp. 239-257.
9. Gorski JC, Jones DR, Wrighton SA, Hall SD. Characterization of dextromethorphan N-demethylation by human liver microsomes. Biochem Pharmacol 1994; 48:173-182.
10. Gotschall RR, Gaedigk A, Simon SD, Kearns GL, Leeder JS. Intra-individual variability in CYP2D6 activity: stability of the urinary dextromethorphan metabolic ratio and detection of drug-drug interactions. Pharmacogenetics 1998; submitted.
11. Haehner BD, Gorski JC, Vandenbranden M, Wrighton SA, Janardan SK, Watkins PB, et al. Bimodal distribution of renal cytochrome P450 3 A activity in humans. Mol Pharmacol 1996; 50:52-59.
12. Jeppesen U, Loft S, Poulsen HE, Brosen K. A fluvoxamine-caffeine interaction study. Pharmacogenetics 1996; 6:213-222.
13. Jones DR, Gorski C, Haehner BD, O'Mara EM Jr., Hall SD. Determination of cytochrome P450 3A4/5 activity in vivo with dextromethorphan N-demethylation. Clin Pharmacol Ther 1996; 60:374-384.
14. Kashuba ADM, Nafziger AN. Physiological changes during the menstrual cycle and their effects on the pharmacokinetics and pharmacodynamics of drugs. Clin Pharmacokinet 1998; 34:203-218.
15. Kashuba ADM, Bertino JS, Rocci ML, Kulawy RW, Beck DJ, Nafziger AN. Quantification of 3-month intraindividual variability and the influence of sex and menstrual cycle phase on CYP3A activity as measured by phenotyping with intravenous midazolam. Clin Pharmacol Ther 1998a; 64:269-277.
16. Kashuba ADM, Nafziger AN, Kearns GL, Leeder JS, Gotschall R, Rocci ML Jr, et al. Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping. Clin Pharmacol Ther 1998b; 64:257-268.
17. Kashuba ADM, Nafziger AN, Kearns GL, Leeder JS, Shirey CS, Gotschall R, et al. Quantification of intraindividual variability and the influence of menstrual cycle phase on CYP2D6 activity as measured by dextromethorphan phenotyping. Pharmacogenetics 1998c; 8:408-410.
18. Kupfer A, Schmid B, Preisig R, Pfaff G. Dextromethorphan as a safe probe for debrisoquine hydroxylation polymorphism. Lancet 1984; 2:517-518.
19. Lam YW, Rodriguez SY. High-performance liquid chromatography determination of dextromethorphan and dextrorphan for oxidation phenotyping by fluorescence and ultraviolet detection. Ther Drug Monit 1993; 15:300-304.
20. Lown KS, Kolars JC, Thummel KE, Barnett JL, Kunze KL, Wrighton ST, et al. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel: lack of prediction by the erythromycin breath test. Drug Metab Dispos 1994; 22:947-955.
21. Lown KS, Bailey DG, Fontana RJ, Janardan SK, Adair CH, Fortlage LA, et al. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J Clin Invest 1997; 99:2545-2553.
22. Olkkola KT, Aranko K, Luurila H, Hiller A, Saarnivaara L, Himberg JJ, Neuvonen PJ. A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther 1993; 53:298-305.
23. Paine MF, Shen DD, Kunze KL, Perkins JD, Marsh CL, McVicar JP, et al. First-pass metabolism of midazolam by the human intestine. Clin Pharmacol Ther 1996; 60:14-24.
24. Park YH, Kullberg MP, Hinsvark ON. Quantitative determination of dextromethorphan and three metabolites in urine by reverse-phase high-performance liquid chromatography. J Pharm Sci 1984; 73:24-29.
25. Pastrakuljic A, Tang BK, Roberts EA, Kalow W. Distinction of CYP1A1 and CYP1A2 activity by selective inhibition using fluvoxamine and isosafrole. Biochem Pharmacol 1997; 53:531-538.
26. Perucca E, Gatti G, Spina E. Clinical pharmacokinetics of fluvoxamine. Clin Pharmacokinet 1994; 27:175-190.
27. Rasmussen BB, Maenpaa J, Pelkonen O, Loft S, Pousen HE, Lykkesfeldt J, et al. Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine. Br J Clin Pharmacol 1995; 39:151-159.
28. Rocci ML, Kulawy RW, Beck DJ. Analysis of midazolam, 1-hydroxymidazolam and 4-hydroxymidazolam in human plasma by LC/MS/MS. J Chrom 1998; submitted.
29. Schmid B, Bircher J, Preisig R, Kupfer A. Polymorphic dextromethorphan metabolism: cosegregation of oxidative O-demethylation with debrisoquine hydroxylation. Clin Pharmacol Ther 1985; 38:618-624.
30. Schmider J, Greenblatt DJ, Fogelman SM, Von Moltke LL, Shader RI. Metabolism of dextromethorphan in vitro: involvement of cytochromes P450 2D6 and 3A3/4, with a possible role of 2E1. Biopharm Drug Disposit 1997; 18:227-240.
31. Schmiedlin-Ren P, Edwards DJ, Fitzsimmons ME, He K, Lown KS, Woster PM, et al. Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents. Drug Met Disp 1997; 25:1228-1233.
32. Schuetz EG, Beck WT, Schuetz JD. Modulators and substrates of p-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol 1996; 49:311-318.
33. Slaughter RL, Edwards DJ. Recent advances: the cytochrome P450 enzymes. Ann Pharmacother 1995; 29:619-624.
34. Spatzenegger M, Jaeger W. Clinical importance of hepatic cytochrome P450 in drug metabolism. Drug Metab Rev 1995; 27:397-417.
35. Thummel KE, Shen DD, Podoll TD, Kunze KL, Trager WF, Hartwell PS, et al. Use of midazolam as a human cytochrome P4503A probe; 1: in vitro-in vivo correlations in liver transplant patients. J Pharmacol Exper Ther 1994a; 271:549-556.
36. Thummel KE, Shen DD, Podoll TD, Kunze KL, Trager WF, Bacchi CE, et al. Use of midazolam as a human cytochrome P4503A probe; II: characterization of inter-and intraindividual hepatic CYP3A variability after liver transplantation. J Pharmacol Ther 1994b; 271:557-566.
37. Thummel KE, O'Shea D, Paine MF, Shen DD, Kunze KL, Perkins JD, et al. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther 1996; 59:491-502.
38. Vetticaden SJ, Cabana BE, Prasad VK, Purich ED, Jonkman JHJ, de Zeeuw R, et al. Phenotypic differences in dextromethorphan metabolism. Pharm Res 1989; 6:13-19.
39. Watkins PB, Murray SA, Winkelman LG, Heuman DM, Wrighton SA, Guzelian PS. Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. J Clin Invest 1989; 83:688-697.
40. Watkins PB. Noninvasive test of CYP3A enzymes. Pharmacogenetics 1994; 4:171-184.
41. Wilkinson GR. Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans. J Pharmacokinet Biopharm 1996; 24:475-490.
42. Zhang Y, Buo X, Lin ET, Benet LZ. Overlapping substrate specificities of cytochrome P450 3A and p-glycoprotein for a novel cysteine protease inhibitor. Drug Metab Disp 1998; 26:360-366.